3 suspended. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Suspended 3 |
| Phase 2 | 1 | Suspended 1 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI). - Coronary Artery Disease, Cognitive Impairment | Phase 3 | Suspended | NYU Langone Health | 1200 | 2026-12-01 | 2026-06-05 |
| A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease GV-971, Placebo - Alzheimer Disease | Phase 3 | Suspended | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | 2046 | 2020-10-27 | 2022-11-23 |
| Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly Hemodynamic target, Phenylephrine, Intravenous fluids - Post-operative Cognitive Dysfunction | Phase 2 / Phase 3 | Suspended | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1812 | 2014-10-01 | 2018-04-13 |
Cognitive Dysfunction (2) · Alzheimer Disease (1) · Coronary Artery Disease (1) · Delirium (1) · Heart Failure (1)
Mental Disorders (3) · Cognition Disorders (2) · Nervous System Diseases (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Confusion (1) · Coronary Disease (1) · Dementia (1) · Heart Diseases (1) · Myocardial Ischemia (1) · Neurobehavioral Manifestations (1)
Coronary Artery Bypass (1) · Dopamine (1) · Ephedrine (1) · Epinephrine (1) · GV-971 (1) · Norepinephrine (1) · Percutaneous Coronary Intervention (1) · Phenylephrine (1)
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Green Valley (Shanghai) Pharmaceuticals Co., Ltd. (1) · NYU Langone Health (1)
Poland (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Hong Kong (1) · India (1) · Italy (1) · Mexico (1) · Netherlands (1) · South Korea (1) · Taiwan (1)
Alessandro Santini, MD (1) · Antonio Pesenti, MD (1) · Luciano Gattinoni, MD, FRCP (1) · Michael Quintel, MD, PhD (1) · S. Bangalore, MD (1) · Thomas Langer, MD (1)